Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 9/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | TYMS | P04818 | 1/20 | 0.47 |
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.43 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3670395 | 0.86 | PNP (0.51) | PNPMEN1KMT2ATLR7ALDH1A1 | |
| SCHEMBL7663886 | 0.86 | PNP (0.51) | PNPMEN1KMT2ATYMSTLR7 | |
| SCHEMBL9798411 | 0.86 | PNP (0.48) | PNPMEN1KMT2ATLR7ALDH1A1 | |
| SCHEMBL6356588 | 0.83 | PNP (0.48) | PNPMEN1KMT2ATLR7ALDH1A1 | |
| SCHEMBL10510960 | 0.82 | MTNR1A (0.55) | PNPMEN1KMT2AALDH1A1CYP3A4 | |
| SCHEMBL2776458 | 0.80 | PNP (0.52) | PNPKMT2ATLR7ALDH1A1CYP3A4 | |
| SCHEMBL18250 | 0.80 | PNP (0.66) | PNPKMT2AADORA3ADORA2B | |
| SCHEMBL10642485 | 0.79 | PNP (0.67) | PNPMEN1KMT2AALDH1A1HPGD | |
| SCHEMBL10505546 | 0.79 | FGFR1 (0.47) | PNPMEN1KMT2AADORA2B | |
| SCHEMBL1980960 | 0.78 | PNP (0.64) | PNPKMT2AADORA3ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1518854-A1 | Substituted 06- benzylguanines and 7- or 9- substituted 8-aza-06-benzylguanines | THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, Department of Health and Human Services (US) | 2005-03-30 | — | — | EP | disclosed |
| US-6436945-B2 | FOR ENHANCING THE CHEMOTHERAPEUTIC TREATMENT OF TUMOR CELLS IN A MAMMAL WITH AN ANTINEOPLASTIC ALKYLATING AGENT, WHICH CAUSES CYTOTOXIC LESIONS AT THE O6-POSITION OF GUANINE; O6-ALKYLGUANINE-DNA ALKYLTRANSFERASE (AGT) INACTIVATOR | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE OF HEALTH AND HUMAN SERVICES | 2002-08-20 | — | — | US | disclosed |
| US-6333331-B1 | USEFUL IN INACTIVATING THE HUMAN DNA REPAIR PROTEIN O.SUP.6 -ALKYLGUANINE-DNA ALKYLTRANSFERASE; ANTICANCER AGENTS | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2001-12-25 | — | — | US | disclosed |
| EP-0374096-B1 | COMBINATION THERAPY INVOLVING 2',3'-DIDEOXYPURINE NUCLEOSIDE AND AN INHIBITOR OF PURINE NUCLEOSIDE PHOSPHORYLASE, AND ITS COMPOSITIONS | CIBA-GEIGY AG (CH) | 1992-12-02 | — | — | EP | disclosed |
| EP-0374096-A1 | Combination therapy involving 2',3'-dideoxypurine nucleoside and an inhibitor of purine nucleoside phosphorylase, and its compositions | CIBA-GEIGY AG (CH) | 1990-06-20 | — | — | EP | disclosed |